Ryan Asay | Vice President of Corporate Affairs |
David Meek | CEO |
James Christensen | Chief Scientific Officer |
Ben Hickey | Chief Commercial Officer |
Vickie Reed | CAO |
Daniel Faga | Chief Commercial Officer |
Chuck Baum | President, Founder and Head of R&D |
Charles Baum - | |
Tyler Van Buren | Cowen |
Neil Carnahan | Stifel |
Gena Wang | Barclays |
Jonathan Miller | Evercore |
Evan Seigerman | BMO Capital Markets |
Michael Ulz | Morgan Stanley |
Carly Kenselaar | Citi |
Andrew Berens | SVB Securities |
Jay Olson | Oppenheimer |
Silvan Tuerkcan | JMP Securities |
Maurice Raycroft | Jefferies |
Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2022 Earnings Call. My name is Kevin, and I will be the operator for today's call. [Operator Instructions] It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.
Thank you, Kevin.